Kevzara

Chemical Namesarilumab
Dosage FormInjection (subcutaneous; 150 mg/1.14 mL, 200 mg/1.14 mL)
Drug ClassMonoclonal antibodies
SystemMusculoskeletal
CompanySanofi-Aventis
Approval Year2017

Indication

  • For treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs
Last updated on 11/2/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Kevzara (sarilumab) Prescribing Information2018sanofi-aventis U.S. LLC, Bridgewater, NJ